Xu Jian, Zhu Hong, Zhao Yaqin, Wang Xin, Shen Yali, Wang Wu, Xu Feng
Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China.
Oncol Lett. 2012 Sep;4(3):471-476. doi: 10.3892/ol.2012.745. Epub 2012 Jun 8.
In the present study, we reviewed 44 postgastrectomy adenocarcinoma patients who had hepatitis B and received treatment in the Abdominal Cancer Department of the West China Hospital between October 2006 and October 2010. Of these patients, 17 developed hepatic dysfunction. Radiotherapy is an independent risk factor to hepatic function on univariate and multivariate analysis. Grade III or IV hepatic dysfunction was developed by five patients, all of whom had received radiotherapy and had reactivated hepatic B virus (HBV). Radiotherapy is a significant risk factor to hepatic function in patients with postgastrectomy adenocarcinoma carrying HBV, thus we suggest excluding the liver from the radiation field. HBV reactivation plays a role in the development of grade III or IV hepatic dysfunction. Patients with reactivated HBV should immediately receive regular antiviral treatment.
在本研究中,我们回顾了2006年10月至2010年10月期间在华西医院腹部肿瘤科接受治疗的44例患有乙型肝炎的胃癌切除术后腺癌患者。在这些患者中,17例出现肝功能障碍。单因素和多因素分析显示,放疗是肝功能的独立危险因素。5例患者出现III级或IV级肝功能障碍,所有这些患者均接受了放疗且乙肝病毒(HBV)重新激活。对于携带HBV的胃癌切除术后腺癌患者,放疗是肝功能的重要危险因素,因此我们建议将肝脏排除在放疗野之外。HBV重新激活在III级或IV级肝功能障碍的发生中起作用。HBV重新激活的患者应立即接受正规抗病毒治疗。